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Abstract
The primary aim of our study was to determine the influence of taking chromium plus carnitine on insulin resistance, with a
secondary objective of evaluating the influences on lipid profiles and weight loss in overweight subjects with polycystic ovary
syndrome (PCOS). In a 12-week randomized, double-blind, placebo-controlled clinical trial, 54 overweight women were ran-
domly assigned to receive either supplements (200 μg/day chromium picolinate plus 1000 mg/day carnitine) or placebo (27/each
group). Chromium and carnitine co-supplementation decreased weight (− 3.6 ± 1.8 vs. − 1.0 ± 0.7 kg, P < 0.001), BMI (− 1.3 ±
0.7 vs. − 0.3 ± 0.3 kg/m2, P < 0.001), fasting plasma glucose (FPG) (− 5.1 ± 6.0 vs. − 1.1 ± 4.9 mg/dL, P = 0.01), insulin (− 2.0 ±
1.4 vs. − 0.2 ± 1.2 μIU/mL, P < 0.001), insulin resistance (− 0.5 ± 0.4 vs. − 0.04 ± 0.3, P < 0.001), triglycerides (− 18.0 ± 25.2 vs.
+ 5.5 ± 14.4 mg/dL, P < 0.001), total (− 17.0 ± 20.3 vs. + 3.6 ± 12.0 mg/dL, P < 0.001), and LDL cholesterol (− 13.3 ± 19.2 vs. +
1.4 ± 13.3 mg/dL, P = 0.002), and elevated insulin sensitivity (+ 0.007 ± 0.005 vs. + 0.002 ± 0.005, P < 0.001). In addition, co-
supplementation upregulated peroxisome proliferator-activated receptor gamma (P = 0.02) and low-density lipoprotein receptor
expression (P = 0.02). Overall, chromium and carnitine co-supplementation for 12 weeks to overweight women with PCOS had
beneficial effects on bodyweight, glycemic control, lipid profiles except HDL cholesterol levels, and gene expression of PPAR-γ
and LDLR. Clinical trial registration number: http://www.irct.ir: IRCT20170513033941N38.
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Introduction
Polycystic ovary syndrome (PCOS) is the most prevalent en-
docrine disorder among women of reproductive age [1]. It is
associated with increased infertility, gestational diabetes
mellitus (GDM), type 2 diabetes mellitus (T2DM), non-
alcoholic fatty liver disease, and cardiovascular disease
(CVD) [2–4]. Hyperinsulinemia increases ovulatory disrup-
tion among PCOS patients [5]. Prior evidence showed that
dyslipidemia including low HDL cholesterol, high LDL cho-
lesterol, and triglycerides levels are common among women
with PCOS [6], as well as reduction in mRNA levels LDL
receptor (LDLR) reduction within adipose tissue of these pa-
tients [7]. The lifestyle modifications including weight loss
and dietary changes are essential for better management of
PCOS [5]. Recently, the beneficial effects of dietary supple-
mentation including zinc and vitamin D among patients with
PCOS are documented in several studies [8, 9].
Carnitine transports free fatty acids into mitochondria;
therefore, it involves in fat metabolism and energy expendi-
ture [10]. In addition, chromiummay play an important role in
decreasing insulin resistance and lipid abnormalities, as well
as weight loss process in the body [11]. Many studies exam-
ined the effects of chromium and carnitine supplementation on
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the metabolic profiles [12–14]. Earlier, it was reported that
chromium supplementation to women with PCOS and diabet-
ic patients significantly improved glucose homeostasis param-
eters and some lipids profiles [12, 15], although several stud-
ies did not report lipid- and glucose-lowering effects of chro-
mium supplements [16]. Previous evidence showed that car-
nitine supplementation had beneficial effects on weight loss,
glycemic control, and lipid profiles in patients with CVD and
PCOS [17, 18].
Previous studies have demonstrated that joint supplemen-
tation of chromium and carnitine is much more efficient in
influencing metabolic profiles that single chromium or carni-
tine supplementation. Several animal studies evaluated the
effects of chromium and carnitine co-supplementation onmet-
abolic profiles. In a study conducted by Zhou et al. [19], yeast
chromium (300 μg/kg diet) and/or L-carnitine (100 mg/kg di-
et) for 8 weeks in sheep reduced insulin levels, while glucose
levels did not change. In addition, Wang et al. [20] found a
significant synergistic effect of chromium and carnitine on
blood glucose in chicken. This evidence suggests that chromi-
um and carnitine may have better effects on glycemic control
and lipid profiles. Therefore, we conducted this study to de-
termine the effects of carnitine and chromium co-
supplementation on body weight, metabolic and genetic pro-
files in overweight and obese women with PCOS.
Subjects and Methods
In a 12-week randomized, double-blind, placebo-controlled
clinical trial, 54 overweight women were randomly assigned
to receive either supplements (200 μg/day chromium
picolinate plus 1000 mg/day carnitine) or placebo (starch)
(27/each group). Carnitine, chromium, and the placebo were
manufactured by Avecinna (Tehran, Iran), twenty-first century
(Arizona, USA), and Barij Essence (Kashan, Iran), respective-
ly. The appearance of the placebo, carnitine, and chromium
capsules, such as color, shape, size, and packaging, were to-
tally similar. Randomization and allocation to intervention
groups were blinded from the researcher and subjects until
the main analyses were completed. At the clinic, a midwife
conducted the randomized allocation sequence, and enrolment
and assignment of the participants to the groups. During the
study, use of carnitine, chromium supplements, and the place-
bos was examined by asking subjects to return the medication
containers and through brief daily cell phone reminders to take
the supplements. Study protocol was published in the Iranian
website for registration of clinical trials (www.irct.ir; no:
IRCT20170513033941N38). Eligible study participants
were overweight and obese women (BMI > 25 kg/m2) with
PCOS diagnosed based on the Rotterdam criteria [21], aged
18–40 years who referred to the outpatient Teleghani Clinic in
Arak, Iran, between June and November 2018. The study
protocol was approved by the Ethics Committee of Arak
University of Medical Sciences (AUMS). Written informed
consent was obtained from all participants prior to the inter-
vention. Exclusion criteria were as follows: pregnancy, adre-
n a l h yp e r p l a s i a , a n d r o g e n - s e c r e t i n g t umo r s ,
hyperprolactinemia, thyroid dysfunction, and diabetes prior
to study inclusion. All subjects completed 3-day diet recall
form at weeks 0, 3, 6, 9, and 12 of the intervention. Dietary
intakes of macro- and micronutrients were calculated by nu-
tritionist IV software (First Databank, San Bruno, CA).
Physical activity was defined as metabolic equivalents
(METs) in hours per day. To calculate the METs for each
participant, we multiplied the times (in hour per day) reported
for each physical activity by its related METs coefficient by
standard tables [22].
Anthropometric Measures
A midwife took anthropometric measurements at the clinic at
baseline and the end of the intervention. Height and weight
(Seca, Hamburg, Germany) were measured light clothing with
shoes removed. Body mass index (BMI) was calculated as
weight (in kilograms) divided by height (in meters) squared.
Assessment of Outcomes
Glycemic control was considered as the primary outcome.
Lipid profiles, peroxisome proliferator-activated receptor
gamma (PPAR-γ), low-density lipoprotein receptor (LDLR),
and glucose transporter 1 (GLUT-1) expression were recog-
nized as the secondary outcomes.
Biochemical Assessment
Fasting blood samples were collected from participants
(15 mL) at weeks 0 and 12 of the intervention. To determine
fasting plasma glucose (FPG) and lipid profiles, enzymatic
kits (Pars Azmun, Tehran, Iran) with inter- and intra-assay
coefficient variances (CVs) lower than 5% were used.
Serum insulin values were assessed using an ELISA kit
(Monobind, California, USA) with the intra- and inter-assay
CVs lower than 6%. The homeostatic model assessment for
insulin resistance (HOMA-IR), homeostatic model
assessment-beta cell function (HOMA-B), and the quantita-
tive insulin sensitivity check index (QUICKI) were deter-
mined according to the suggested formulas [23].
RNA Extraction and Real-Time PCR
PPAR-γ, GLUT-1, and LDLR expression were evaluated by
quantitative RT-PCR, using the LightCycler technology
(Roche Diagnostics, Rotkreuz, Switzerland) with SYBR
green detection and Amplicon Kit (Table 1).
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Statistical Analyses
In the present study, we used sample size estimation for-
mula for randomized clinical trials where type one (α) and
type two errors (β) were 0.05 and 0.20 (power = 80%),
respectively. According to a previous study [18], we used
1.03 as SD and 0.83 as the change in mean (d) of HOMA-
IR as a main variable. Based on the formula, we needed
25 patients in each group; after considering 20% dropout
in each group, the final sample size was 30 participants in
each group.
The Kolmogorov-Smirnov test was done to determine
the normality of variables. Independent sample t test was
done to compare changes in anthropometric values and
dietary intakes between the two groups. Two-way analysis
of variance (ANOVA) for repeated measures was done to
compare changes in gene expression related to PPAR-γ,
GLUT-1, and LDLR between the two groups. To deter-
mine the effects of chromium and carnit ine co-
administration on metabolic profiles, we used two-way
ANOVA for repeated measures. In these analyses, the
treatments (placebo and chromium plus carnitine groups)
were regarded as between-subject factors and time was
considered as within-subject factor. Significance of the
treatment effects was presented as the mean differences
with 95% confidence interval. P values < 0.05 were con-
sidered statistically significant.
Results
During the treatment, six participants dropped out of the study
due to personal reasons (n = 3 each group) (Fig. 1). Finally, 54
participants [placebo (n = 27) and supplements (n = 27)] com-
pleted the trial.
The mean age, height, BMI, and weight of patients at base-
line and after the 12-week intervention were not significant
(Table 2).
The mean intake of macro- and micronutrients during the
treatment was not significant between the two groups
(Table 3).
Chromium and carnitine co-supplementation decreased
weight (− 3.6 ± 1.8 vs. − 1.0 ± 0.7 kg, P < 0.001), BMI (−
1.3 ± 0.7 vs. − 0.3 ± 0.3 kg/m2, P < 0.001) (Table 2), FPG (−
5.1 ± 6.0 vs. − 1.1 ± 4.9 mg/dL, P = 0.01), insulin (− 2.0 ± 1.4
vs. − 0.2 ± 1.2 μIU/mL, P < 0.001), HOMA-IR (− 0.5 ± 0.4
vs. − 0.04 ± 0.3, P < 0.001), triglycerides (− 18.0 ± 25.2 vs.
+ 5.5 ± 14.4 mg/dL, P < 0.001), total (− 17.0 ± 20.3 vs. + 3.6
± 12.0 mg/dL, P < 0.001) and LDL cholesterol (− 13.3 ± 19.2
vs. + 1.4 ± 13.3 mg/dL, P = 0.002), and elevated QUICKI (+
0.007 ± 0.005 vs. + 0.002 ± 0.005, P < 0.001) (Table 4). In
addition, co-supplementation upregulated PPAR-γ (P =
0.02) and LDLR expression (P = 0.02) (Fig. 2).
Discussion
In the current study, we investigated the effects of chromium
and carnitine co-supplementation for 12 weeks on body
weight, glycemic control, lipid concentrations, and gene ex-
pression related to insulin and lipid among women with
PCOS. We found that taking combined chromium and carni-
tine supplements by women with PCOS significantly im-
proved body weight, BMI, glycemic control, lipid parameters
except HDL cholesterol levels, and gene expression related to
insulin and lipid.
Effects on Body Weight and BMI
PCOS patients due to hyperinsulinemia and androgen excess
are susceptible to an increased body weight which is associ-
ated with further reduction in insulin sensitivity and elevated
the risk of metabolic syndrome [4]. We found that chromium
and carnitine co-supplementation for 12weeks to women with
PCOS significantly decreased weight and BMI. Our findings
were in consistent with the results of some meta-analyses
Table 1 Specific primers used for real-time quantitative PCR
Gene Primer Product size (bp) Annealing temperature (C)
GAPDH F: AAGCTCATTTCCTGGTATGACAACG 126 61.3
R: TCTTCCTCTTGTGCTCTTGCTGG
PPAR-γ F: ATGACAGACCTCAGACAGATTG 210 54
R: AATGTTGGCAGTGGCTCAG
GLUT-1 F: TATCTGAGCATCGTGGCCAT 238 62.1
R: AAGACGTAGGGACCACACAG
LDLR F: ACTTACGGACAGACAGACAG 223 57
R: GGCCACACATCCCATGATTC
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GLUT-1, glucose transporter 1; LDLR, low-density lipoprotein receptor; PPAR-γ, peroxisome
proliferator-activated receptor gamma
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evaluating the effects of chromium or carnitine supplementa-
tion on weight and BMI [24–26]. However, in a meta-analy-
sis, chromium supplementation did not reduce BMI among
women with PCOS [27]. The controversial findings might
be mediated by different study designs, baseline values of
measured variables, baseline levels of chromium and carni-
tine, different dosages, and type of chromium and carnitine
used as well as different participants’ characteristics.
Chromium may reduce body weight by insulin sensitizing
effects, stimulating thermogenesis, and suppressing the appe-
tite through stimulating insulin-sensitive glucoreceptors in the
brain [21]. Carnitine contributes to activation of the glycolytic
pathways and has an important role in fat metabolism by
transformation of long-chain fatty acids across the mitochon-
drial membrane and due to the effects on glucose and lipid
metabolism increase energy expenditure which in turn may
help weight loss [24].
Effects on Glycemic Control
In the current study, we observed the favorable effects of
chromium and carnitine co-supplementation on glycemic sta-
tus for 12 weeks among PCOS subjects. On the basis of avail-
able researches, chromium supplementation may have some
Randomized (n = 60)
Allocated to placebo (n = 30)
Lost to follow-up due to
personal reasons (n = 3)
Analyzed (n = 27)
Allocated to intervention (n = 30) 
Lost to follow-up due to personal
reasons (n = 3) 
Analyzed (n = 27)
Assessed for eligibility (n = 65)
Excluded (n = 5)























Fig. 1 Summary of patient flow
diagram
Table 2 General characteristics of study participants1
Placebo group (n = 27) Chromium and carnitine group (n = 27) P2
Age (y) 27.4 ± 5.3 29.6 ± 4.3 0.15
Height (cm) 164.7 ± 6.0 163.0 ± 4.9 0.25
Weight at study baseline (kg) 75.6 ± 5.9 77.6 ± 9.1 0.41
Weight at end-of-trial (kg) 74.8 ± 6.0 73.9 ± 8.7 0.67
Weight change (kg) − 1.0 ± 0.7 − 3.6 ± 1.8 < 0.001
BMI at study baseline (kg/m2) 28.0 ± 2.3 29.1 ± 2.8 0.10
BMI at end-of-trial (kg/m2) 27.6 ± 2.2 27.8 ± 2.7 0.78
BMI change (kg/m2) − 0.3 ± 0.3 − 1.3 ± 0.7 < 0.001
MET-h/day at study baseline 26.2 ± 1.8 26.7 ± 1.6 0.27
MET-h/day at end-of-trial 26.5 ± 1.8 27.1 ± 1.5 0.19
MET-h/day change 0.3 ± 0.5 0.4 ± 0.4 0.53
1Data are means ± SDs
2Obtained from independent t test. METs, metabolic equivalents
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beneficial effects on glycemic control. Suksomboon et al. [12]
demonstrated that chromium supplementation significantly
reduced FPG and HbA1c in diabetic patients. In addition,
Samimi et al. [18] indicated that carnitine supplementation
led to a significant reduction in FPG, insulin levels and
HOMA-IR, but did not affect QUICKI. However, Fazelian
et al. [26] reported that taking chromium by PCOS women
did not influence FPG. Moreover, Tang et al. [27] found that
chromium supplementation to women with PCOS decreased
HOMA-IR and had no beneficial effects on other parameters
of glycemic control, including FPG, insulin, and QUICKI.
Decreased glucose levels by chromium is accompanied by
an increase in hepatic glucose uptake, the activity of glycolytic
enzymes, including glucokinase, phosphofructokinase, and
pyruvate kinase [28]. In consistent with our study, the results
of a meta-analysis by Xu et al. [29] revealed that carnitine
could improve HOMA-IR. Vidal-Casariego et al. [30] also
reported that carnitine supplementation in T2DM patients re-
duced FPG, but did not influence HbA1c. In addition, a 12-
month treatment with orlistat plus carnitine compared with
orlistat alone resulted in a better improvement in FPG,
HbA1C, and HOMA-IR among uncontrolled T2DM subjects
[31]. However, Derosa et al. [32] did not find any significant
effect of 6-month carnitine consumption on fasting glucose,
HbA1C and insulin levels in hypercholesterolemic T2DM
subjects. Suggested mechanisms supporting favorable effects
of carnitine on glucose metabolism include increasing mito-
chondrial oxidation of long-chain fatty acids, which in turn
reduce insulin resistance, modulating pyruvate dehydrogenase
complex activity, regulating gene expression of glycolytic and
gluconeogenic enzymes, stimulating of insulin and insulin-
like growth factor-1 cascade [10].
Our findings showed that chromium and carnitine co-
supplementation increased gene expression of PPAR-γ, but
did not affect gene expression of GLUT-1. Several studies
have evaluated the effects of chromium or carnitine supple-
mentation to these genetic responses. Administration of chro-
mium picolinate alone or in combination with biotin increased
PPAR-γ expression in type 2 diabetic rat model [33]. Animal
experiments have reported that carnitine or its derivatives sup-
plementation improved glucose and lipid metabolism by reg-
ulation of PPAR-γ, GLUT-2 and GLUT-4 mRNA expression
[34, 35]. In addition, in vitro treatment of rat sertoli cell with
carnitine and L-acetylcarnitine alone and in combination in-
creased mRNA expression of GLUT-1 and decreased of
insulin-like growth factor binding protein-4 mRNA [36].
PPAR-γ mainly expresses in adipose tissue and involves in
the reduction of insulin resistance, modification of glucose
metabolism and lipid storage [37, 38]. It may regulate early
stages in gene expression of GLUT-4 [39].
Effects on Lipid Parameters
In the current trial, we observed beneficial effects of chromi-
um and carnitine co-administration on lipid profiles except
HDL cholesterol levels among women with PCOS.
Currently, we demonstrated that chromium administration
for 8 weeks to PCOSwomen candidate for in vitro fertilization
significantly decreased total, VLDL cholesterol, and triglyc-
erides levels, but did not affect other lipid profiles [40].
Although in some studies, chromium supplementation did
not affect lipid parameters among patient with metabolic dis-
eases [15, 41]. Chromium may improve lipid metabolism
through altering the activity of lipoprotein lipase and
Table 3 Mean dietary intakes of study participants throughout the study
Placebo group (n = 27) Chromium and carnitine group (n = 27) P1
Energy (kcal/d) 2252 ± 172 2327 ± 277 0.24
Carbohydrates (g/d) 307.9 ± 50.1 318.8 ± 59.6 0.47
Protein (g/d) 85.5 ± 15.1 83.5 ± 13.6 0.61
Fat (g/d) 78.5 ± 13.5 83.4 ± 16.7 0.23
SFAs (g/d) 23.0 ± 6.2 16.4 ± 2.1 0.47
PUFAs (g/d) 26.3 ± 5.3 28.1 ± 7.4 0.31
MUFAs (g/d) 20.4 ± 5.2 21.6 ± 5.8 0.42
Cholesterol (mg/d) 202.0 ± 125.9 223.4 ± 132.6 0.54
TDF (g/d) 16.9 ± 4.4 17.8 ± 5.5 0.49
Chromium (μg/d) 34.1 ± 10.7 36.5 ± 10.9 0.65
Magnesium (mg/d) 260.4 ± 43.7 270.7 ± 66.5 0.50
Zinc (mg/d) 9.6 ± 2.7 9.6 ± 2.5 0.97
Manganese (mg/d) 2.0 ± 0.7 2.1 ± 0.8 0.55
Data are means ± SDs
1Obtained from independent t test
MUFAs, monounsaturated fatty acids; PUFAs, polyunsaturated fatty acids; SFAs, saturated fatty acids; TDF, total dietary fiber
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inhibiting the transcription of rate limiting enzymes in the fat
synthesis pathway, such as fatty acid synthetase and acetyl-
coA carboxylase [19]. A number of animal and human studies
have evaluated the effects of carnitine on lipid profiles.
Similar to our findings, Lee et al. [17] reported that a 12-
week supplementation with carnitine decreased triglycerides.
Moreover, carnitine supplementation for 12 weeks in diabetic
patients led to a significant reduction in total, LDL cholesterol,
and triglycerides, while HDL cholesterol levels were in-
creased [42]. A meta-analysis conducted by Vidal-Casariego
et al. [30], it was observed that carnitine supplementation to
T2DM patients reduced total and LDL cholesterol, but did not
affect triglycerides and HDL cholesterol levels. However,
Derosa et al. [32] did not report any significant improvement
in total, LDL, and HDL cholesterol and triglycerides levels
following the supplementation of carnitine in hypercholester-
olemic people with T2DM. The different findings might be
explained by kind of chromium used, baseline circulating
levels of chromium and carnitine, different study designs as
well as different participants of the study. Carnitine facilitates
transportation of activated long-chain fatty acids from the cy-
tosol to mitochondria. It also changes the triglycerides synthe-
sis and esterification toward the formation of acetylcarnitines,
which in turn decrease the plasma concentration of triglycer-
ides and VLDL cholesterol values [43].
In the present study, we found that LDL-R expression in-
creased in response to the intervention. There are few studies
investigating the effects of chromium and carnitine on gene
Table 4 Metabolic profiles at baseline and after the 12-week intervention in women with polycystic ovary syndrome that received either carnitine plus
chromium supplements or placebo1
Placebo group (n = 27) Chromium and carnitine group (n = 27) P2
Wk0 Wk12 Change Wk0 Wk12 Change
FPG (mg/dL) 93.5 ± 6.4 92.4 ± 7.3 − 1.1 ± 4.9 94.1 ± 10.4 89.0 ± 8.4 − 5.1 ± 6.0 0.01
Insulin (μIU/mL) 11.5 ± 2.2 11.3 ± 2.7 − 0.2 ± 1.2 12.5 ± 2.1 10.5 ± 1.7 − 2.0 ± 1.4 < 0.001
HOMA-IR 2.6 ± 0.5 2.6 ± 0.6 − 0.04 ± 0.3 2.9 ± 0.6 2.4 ± 0.4 − 0.5 ± 0.4 < 0.001
HOMA-B 141.2 ± 40.1 144.3 ± 44.5 3.1 ± 17.7 190.5 ± 200.3 181.7 ± 142.7 − 8.8 ± 128.9 0.63
QUICKI 0.33 ± 0.01 0.33 ± 0.01 0.002 ± 0.005 0.32 ± 0.009 0.33 ± 0.008 0.007 ± 0.005 < 0.001
Triglycerides (mg/dL) 159.0 ± 35.1 164.5 ± 33.2 5.5 ± 14.4 154.4 ± 49.7 136.4 ± 38.4 − 18.0 ± 25.2 < 0.001
VLDL cholesterol (mg/dL) 31.8 ± 7.0 32.9 ± 6.5 1.1 ± 2.9 30.9 ± 9.9 27.3 ± 7.7 − 3.6 ± 5.0 < 0.001
Total cholesterol (mg/dL) 192.0 ± 35.1 195.6 ± 34.6 3.6 ± 12.0 202.9 ± 45.6 185.9 ± 36.0 − 17.0 ± 20.3 < 0.001
LDL cholesterol (mg/dL) 109.8 ± 38.5 111.2 ± 39.2 1.4 ± 13.3 123.9 ± 39.9 110.6 ± 33.1 − 13.3 ± 19.2 0.002
HDL cholesterol (mg/dL) 50.4 ± 6.0 51.4 ± 8.7 1.0 ± 7.3 48.0 ± 10.9 48.0 ± 9.3 − 0.03 ± 5.8 0.56
Total-/HDL cholesterol ratio 3.8 ± 0.9 3.9 ± 1.0 0.1 ± 0.6 4.3 ± 1.0 4.0 ± 0.8 − 0.3 ± 0.7 0.01
1All values are means ± SDs
2P values represent the time × group interaction (computed by analysis of the repeated measures ANOVA)
FPG, fasting plasma glucose; HOMA-IR, homeostasis model of assessment-insulin resistance; homeostasis model of assessment-estimated b cell
function; HDL cholesterol, high density lipoprotein cholesterol; LDL cholesterol, low-density lipoprotein cholesterol; QUICKI, quantitative insulin










































Fig. 2 Fold change (means ± SDs) in gene expression levels of PPAR-γ,
GLUT-1, and LDLR inwomenwith polycystic ovary syndrome receiving
chromium plus carnitine supplements and placebo. P value was obtained
from two-way ANOVA for repeated measures. N = 27 in each group.
GLUT-1, glucose transporter 1; LDLR, low-density lipoprotein receptor;
PPAR-γ, peroxisome proliferator-activated receptor gamma; PCOS,
polycystic ovary syndrome
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expression related to lipid metabolism. Lee et al. [44] reported
that adding chromium picolinate to intravenous glucose infu-
sion in Korean native steers improved lipid metabolism and
gene expression of fatty acid synthase and stearoyl-CoA
desaturase-1. In addition, a 10-week hypocaloric high-
protein diet and carnitine supplementation increased expres-
sion of LDLR and lipoprotein lipase mRNA [45]. Some ani-
mal studies investigating combined chromium and carnitine
found an interactive effect on several lipid parameters. Wang
et al. [20] found a significant interactive effect between chro-
mium and L-carnitine on total, HDL cholesterol, triglycerides
and free fatty acids in chicken. Another animal investigation
reported that chromium picolinate in combination with carni-
tine reduced non-esterified fatty acids concentrations which
could reflect improved fatty acids utilization [46]. Although,
the authors observed that combined supplementation had no
significant effect on triglyceride levels [46].
Conclusions
Overall, chromium and carnitine co-supplementation for
12 weeks to overweight women with PCOS had beneficial
effects on body weight, glycemic control, lipid profiles except
HDL cholesterol levels, and gene expression of PPAR-γ and
LDLR. This suggests consumption of chromium plus carni-
tine supplements may confer advantageous therapeutic poten-
tial for overweight women with PCOS. Further studies are
needed in other patients and with longer periods to determine
the beneficial effects of chromium and carnitine co-
supplementation.
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